PharmaTelevision - ChinaBio LLC: Opportunities for Chinese Biotech

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: ChinaBio LLC: Opportunities for Chinese Biotech

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Ian Wisenberg at ChinaBio LLC. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

ChinaBio 's focus and perspective on biotechnology developments in China.

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Barcelona at BioEurope. On this show I have Ian Wisenberg, who is Senior Vice President of Strategic Development at ChinaBio , you are based in San Diego but you serve the China and US access I can describe it I suppose, Ian Wisenberg what are you doing here at Barcelona?

Ian Wisenberg:

Well you positioned that correctly, I mean the effective ingredient for us is to bridge the Pacific by clearly Europe is a major part of that equation too because Europe has an access or needs an access to try and seize the opportunity there as well and we certainly want to help ourselves and our clients position themselves both to access Europe and as well to access China.

Fintan Walton:

Okay. So let's look at that because clearly China is one of these incredible emerging countries at the moment particularly in pharmaceuticals, companies normally look at China as a centre for manufacturing but there is lots of things happening there and there is a biotech sector that's emerging, from ChinaBio 's perspective what is the focus? what do you look at any specific part of the developments in China?

Ian Wisenberg:

We look at the full value chain. You have been correct the genesis of China market has always been had been the service based industry and manufacturing. In the life sciences obviously the CRO market is very strong, companies saw the opportunity for higher quality low cost and it was taking advantage of that for several years and of course the success of Roche is a good example of that fact that this is a really good model, there are several large players in China. But what we want to try to do and help companies understand is that the drug discovery and development equation is evolving pretty rapidly in China and not these are which the government support for innovation. They launched a few programs obviously healthcare is a big issue in China so they've launched a big program $124 billion to essentially right size the healthcare provide healthcare and across the entire spectrum. $12 billion dedicated to biotechnology so there is a lot of money behind the effort for drug discovery and development and other molecules I mean not just another me too's or generics and so to speak but they want to bring healthcare to China.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Ian Wisenberg

Senior Vice President

Ian Wisenberg serves as ChinaBio LLC 's chief liaison with key executives and investors in the US. Formerly Senior Vice President and CFO of BIOCOM, the largest regional life science association in the US, Mr. Ian Wisenberg also led BIOCOM's Capital Development initiative and built its "VC incubator" in San Diego. He brings over 25 years of experience in international finance, business development and administration, and serves on the board of two biotech companies.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

ChinaBio LLC

ChinaBio LLC : The story of ChinaBio starts with a vacation In November 2006, our founder, Greg Scott, visited China for the first time. He had arranged to have one business meeting while he was in Shanghai at Zhangjiang Hi-Tech Park. From that single meeting, and a brief tour of the 25 sq. km Park where he saw Roche, Pfizer, GSK, Lilly, and over 200 early-stage biotech companies, he knew he would be coming back to China. His 10-years of experience as an angel investor in biotech in the US led him to believe that there was something "big" happening in China, and he had to find out more. So in late January 2007, he returned for one week with only two scheduled meetings. By the end of the week and over 30 meetings, the seeds of ChinaBio LLC were sown. By April, ChinaBio 's offices were open in the Biotech VC Plaza building in Zhangjiang Hi-Tech Park, and the first staff was hired. While often told he was one of the very few interested in early-stage biotech/medtech in China, his interest remained high as he worked with several promising companies.